News Releases

Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference

CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ: NUVL), a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will participate in a virtual fireside chat during the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 14, 2022, at 9:00 a.m. ET.

A live webcast will be available in the investor section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.
 

 

SOURCE Nuvalent, Inc.
 

Investor Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media Contact:
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com